Global Subcutaneous Biologics Market Overview
The key driver impacting the subcutaneous biologics market is the growing prevalence of rheumatoid arthritis, breast cancer, and Crohn's diseases globally. For instance, the World Cancer Research Fund reports estimations; Breast cancer is the most common cancer occurring in women globally. In 2012 around 1.7 million new cases have been diagnosed, accounting for 25 percent of all cancers in women. It is 2018; it increased to 2.1 million newly diagnosed female breast cancer cases in 2018. As per the Center for Disease Control and Prevention, In 2015, an expected 1.3% of U.S. adults (3 million) were being diagnosed with IBD (either Crohn's disease or ulcerative colitis). It was a significant rise from 1999 (0.9% or 2 million adults). Moreover, the Introduction of innovative drug delivery devices such as auto-injectors and prefilled syringes is estimated to be a significant factor contributing to market growth.
According to Value Market Research, the global subcutaneous biologics market size was valued at around USD 122.5 billion in 2020 and is projected to grow at a CAGR of about 12.5% during the forecast period of 2021 to 2027.
The subcutaneous administration route offers significant advantages over intravenous administration is estimated to augment subcutaneous biologics demand in the forecast period. For instance, such as easiness of drug administration does not necessitate skilled personnel for drug administration, facilitate at-home drug delivery, decrease patient time at healthcare facilities, condense medicine costs, and augment therapy compliance. Growing cases for rheumatoid arthritis(RA) are likely to create more demand for subcutaneous biologics in the coming years. As per the Rheumatoid Arthritis organization, RA is a chronic disease that affects around 1.3 million Americans and approximately 1% of the global population. It is expected that over 300,000 children in the United States undergo juvenile RA. However, the high risk of allergic reactions may hamper the global subcutaneous biologics market in the long run. Also, the strict regulatory requirement for subcutaneous biologics' approval is negatively impacting the market growth in the forecast period. The current industry trends, such as the rising trend of self-medication, expanding biosimilars market, are expected to provide market players with new market opportunities.
The subcutaneous biologics market is vast, with many local and global players. The key leaders follow different strategies to advance their market position, such as contracts, amalgamation, getting biologics license from regulatory authorities(FDA), extending product portfolio, acquisitions, and product upgrades to raise their market share across the globe. For instance, in July 2018, Halozyme Therapeutics, Inc. declared that the U.S. Food and Drugs Administration (FDA) acknowledged a biologics license from 'Genentech,' a Roche Group member, for the subcutaneous formulation of trastuzumab (Herceptin). It is the company's FDA-approved indication for the treatment of breast cancer. The major players in the report are Biogen Idec, Amgen, Inc., Genentech Inc., F. Hoffmann-La Roche AG, AbbVie, Inc., Eisai, Inc., Takeda Pharmaceutical Company Ltd., Pfizer Ltd., and Bristol-Myers Squibb.
In this research report, the subcutaneous biologics market is segmented by subcutaneous drug delivery systems, applications, and regions.
Analysis by Subcutaneous Drug Delivery Systems:
By subcutaneous drug delivery systems, the report is categorized into prefilled syringes, wearable injectors, auto-injectors, and drug reconstitution delivery systems, and others. The prefilled syringes segment dominates the subcutaneous drug delivery systems segment with over 20% share in 2020. It is a highly effective biologics and drug administration routes such as proteins, antibodies, peptides, and other large and complex molecules. Moreover, the increasing trend of self-medication and requirement of high concentration subcutaneous formulation of biologics driving demand for prefilled syringes in the forecast period.
Analysis by Applications:
By applications, the report is categorized into Crohn's diseases, rheumatoid arthritis, breast cancer, leukemia, lymphoma, and psoriasis. The Crohn’s disease segment dominates the application segment with over 25% share in 2020. It is due to the growing cases of Crohn’s disease globally. Moreover, the High adoption rate of viscous biologics in treating chronic conditions with increasing awareness about the benefits of biologics over other treatment methods contributes to the high market demand for Crohn's disease treatment in the forecast period.
Analysis by Region:
In the regional outlook of the global subcutaneous biologics market, the North America region dominates with a 30% market share during the forecast period. It is due to the high prevalence of rheumatoid arthritis and breast cancer across the United States and Canada. Also, Canada has the most increased occurrence of Crohn's across the globe. Moreover, the rising healthcare expenditure and high adoption rate and approval of biologics by the U.S. Food and Drugs Administration (FDA) contribute to the development of the subcutaneous biologics market in North America.
Market Segmentation covered in the Report:
By Subcutaneous Drug Delivery Systems
- Prefilled Syringes
- Wearable Injectors
- Drug Reconstitution Delivery Systems.
- Crohn’s Disease
- Rheumatoid Arthritis
- Breast Cancer
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.